Observational studyInternational journal of clinical oncology2026
Effectiveness of first-line combination chemotherapy in older patients with unresectable advanced gastric cancer: a retrospective study.
Observational study in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombination therapy is the standard treatment for curatively unresectable gastric cancer; however, its effectiveness in patients aged ≥ 75 years remains unclear. This study investigated the effectiveness of combination therapy in enhancing overall survival.
methodsWe retrospectively analyzed nationwide medical claims data for patients with unresectable advanced gastric cancer who received chemotherapy between October 2010 and May 2023. Overall survival and real-world progression-free survival were the primary and secondary outcomes, respectively. Patient characteristics were adjusted using inverse probability of treatment weighting, and inverse probability of treatment weighting-adjusted hazard ratios were calculated.
resultsAmong 6213 patients (mean age 80.0 years, 70.3% men), 4988 received monotherapy and 1225 received combination therapy. The median (interquartile range) number of first-line therapy cycles and duration of first-line therapy were three cycles and 4.4 (2.1-7.9) months for monotherapy and four cycles and 5.3 (2.7-9.1) months for combination therapy, respectively. The median overall survival was 9.7 and 11.3 months (significant adjusted hazard ratio) while real-world progression-free survival was 4.4 and 5.1 months (significant adjusted hazard ratio) for monotherapy and combination therapy, respectively. In multivariate analysis, the adjusted hazard ratio for overall survival was not significant.
conclusionsAfter adjusting for background factors, compared with monotherapy, combination therapy did not extend overall survival; however, an extension of real-world progression-free survival was observed. These results suggest that combination therapy is an effective treatment option for older patients with unresectable gastric cancer. Further studies considering the systemic condition of older patients are necessary.
Indexed as
Identifiers
41649665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.